Conestat alfa for the treatment of angioedema attacks

Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its current treatment modalities and focuses on findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement products because it is produced from transgenic rabbits rather than derived from human plasma donors, which can potentially allow an unlimited source of drug without any concern of infectious transmission. The clinical trial data generated to date indicate that conestat alfa is safe and effective for the treatment of acute HAE attacks.

[1]  M. Mannesse,et al.  Immunogenicity Assessment of Recombinant Human C1-Inhibitor , 2012, BioDrugs.

[2]  J. Bernstein,et al.  Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema , 2010, Journal of cardiothoracic surgery.

[3]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[4]  Pedro Mejia,et al.  C1 inhibitor, a multi-functional serine protease inhibitor , 2010, Thrombosis and Haemostasis.

[5]  T. Klingebiel,et al.  Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. , 2010, American journal of obstetrics and gynecology.

[6]  P. Keith,et al.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[7]  D. Wouters,et al.  C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor , 2008 .

[8]  K. Bork,et al.  Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  B. Zuraw.  Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[10]  A. Davis.  Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  M. V. van Ham,et al.  C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. , 2008, Expert opinion on biological therapy.

[12]  J. Bernstein.  Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  A. Sheffer,et al.  Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  I. Bernstein,et al.  Hereditary angioedema: a current state-of-the-art review, II: historical perspective of non-histamine-induced angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  H. Farkas,et al.  Management of Hereditary Angioedema in Pediatric Patients , 2007, Pediatrics.

[16]  H. Schuitemaker,et al.  Viral safety of C1-inhibitor NF. , 2007, Biologicals : journal of the International Association of Biological Standardization.

[17]  P. Schlattmann,et al.  Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.

[18]  H. Farkas,et al.  Recombinant human C1‐inhibitor in the treatment of acute angioedema attacks , 2007, Transfusion.

[19]  T. Craig,et al.  Fresh frozen plasma for the treatment of hereditary angioedema. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  M. Frank.  Hereditary angioedema: the clinical syndrome and its management in the United States. , 2006, Immunology and allergy clinics of North America.

[21]  J. Levy,et al.  The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema , 2006, Expert opinion on investigational drugs.

[22]  K. Bork,et al.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.

[23]  O. Frazier,et al.  Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: possible association with antifibrinolytic therapy. , 2006, The Journal of thoracic and cardiovascular surgery.

[24]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[25]  A. Eerenberg,et al.  A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[26]  H. Longhurst.  Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? , 2005, International journal of clinical practice.

[27]  M. López-Trascasa,et al.  Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[28]  J. Kamerling,et al.  Influence of lactation parameters on the N-glycosylation of recombinant human C1 inhibitor isolated from the milk of transgenic rabbits. , 2004, Glycobiology.

[29]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[30]  T. Krieg,et al.  Efficacy of danazol treatment in a patient with the new variant of hereditary angio‐oedema (HAE III) , 2004, The British journal of dermatology.

[31]  J. Kamerling,et al.  N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. , 2003, Glycobiology.

[32]  Anthony Williams,et al.  DX-88 and HAE: a developmental perspective. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[33]  M. Cicardi,et al.  How do we treat patients with hereditary angioedema. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[34]  K. Bork,et al.  Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. , 2003, Archives of internal medicine.

[35]  J. Weiler,et al.  Expression of C1 esterase inhibitor by the baculovirus expression vector system: preparation, purification, and characterization. , 2001, Protein expression and purification.

[36]  T. Lamark,et al.  Expression of active human C1 inhibitor serpin domain in Escherichia coli. , 2001, Protein expression and purification.

[37]  K. Bork,et al.  Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. , 2001, Archives of internal medicine.

[38]  S. Mohri,et al.  Scrapie removal using Planova virus removal filters. , 2001, Biologicals : journal of the International Association of Biological Standardization.

[39]  M. Cicardi,et al.  Angioedema due to angiotensin-converting enzyme inhibitors. , 1999, Immunopharmacology.

[40]  M. Cicardi,et al.  Pathogenetic and clinical aspects of C1 inhibitor deficiency. , 1998, Immunobiology.

[41]  G. Horstick,et al.  Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. , 1997, Circulation.

[42]  M. Cicardi,et al.  Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. , 1997, The Journal of allergy and clinical immunology.

[43]  Beverly D Seymour,et al.  Rhabdomyolysis Induced by Epsilon-Aminocaproic Acid , 1997, The Annals of pharmacotherapy.

[44]  F. Rosen,et al.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.

[45]  J. Gran,et al.  Hereditary angio‐oedema: new clinical observations and autoimmune screening, complement and kallikrein‐kinin analyses , 1996, Journal of internal medicine.

[46]  A. M. Lefer,et al.  Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. , 1995, Circulation.

[47]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[48]  C. Hack,et al.  Characterization of recombinant C1 inhibitor P1 variants. , 1992, The Journal of biological chemistry.

[49]  E. Hack,et al.  Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. , 1991, The Journal of allergy and clinical immunology.

[50]  M. Frank,et al.  Oral manifestations and dental management of patients with hereditary angioedema. , 1991, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[51]  C. Hack,et al.  Proteolytic inactivation of plasma C1- inhibitor in sepsis. , 1989, The Journal of clinical investigation.

[52]  C. Hack,et al.  Expression of functional human C1 inhibitor in COS cells. , 1988, The Journal of biological chemistry.

[53]  P. Carter,et al.  Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins. , 1988, European journal of biochemistry.

[54]  B. Wüthrich,et al.  Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. , 1984, Complement.

[55]  M. Cicardi,et al.  Hereditary Angioedema: An Appraisal of 104 Cases , 1982, The American journal of the medical sciences.

[56]  A. Sheffer,et al.  Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. , 1981, The Journal of allergy and clinical immunology.

[57]  E. Brown,et al.  Long-term therapy of hereditary angioedema with danazol. , 1980, Annals of internal medicine.

[58]  M. Cicardi,et al.  Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. , 1980, The Journal of allergy and clinical immunology.

[59]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[60]  J. Atkinson,et al.  Hereditary angioedema: the clinical syndrome and its management. , 1976, Annals of internal medicine.

[61]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[62]  J. Atkinson,et al.  Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. , 1975, The Journal of allergy and clinical immunology.

[63]  G. Blohmé.  Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. , 2009 .

[64]  D. Alling,et al.  Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. , 1972, The New England journal of medicine.